How Gilead Lost $7.8B in October Alone Post author:Sam Post published:November 2, 2017 Post category:BioPharma Gilead Sciences’ third-quarter financial results were dismal, to say the least. Source: BioSpace You Might Also Like Lysogene Pushes Forward With Sanfilippo Syndrome Study, Establishes Footprint in U.S. October 24, 2017 Future Biotech Giants: 11 Life Science Entrepreneurs Under 30 February 22, 2017 Top GlaxoSmithKline Investor Cashes Out, Citing a Weak Pipeline and Lack of Strategic Options May 11, 2017
Lysogene Pushes Forward With Sanfilippo Syndrome Study, Establishes Footprint in U.S. October 24, 2017
Top GlaxoSmithKline Investor Cashes Out, Citing a Weak Pipeline and Lack of Strategic Options May 11, 2017
